Axil Brands, Inc. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
AXIL Brands reported Q1 FY2027 net revenues of $6.1M (down 11.2% YoY from $6.9M) due to XCOR transition and non-repeating prior-year big-box order. However, new XCOR II product announced August 26 generated $3.6M in orders by September 30, 2026, with shipments underway in Q2. Net income was $0.4M ($0.05/diluted share) vs. $0.3M ($0.04) prior year; gross margin improved to 82.6% including $0.55M non-recurring customs duty refund; cash position strengthened to $7.9M from $4.5M; company divested 25% of Reviv3 to three strategic partners for $137.5K equity (retaining 75%).
Why this rating
Revenue decline is modest headwind but offset by strong XCOR II pre-launch orders ($3.6M equals 59% of quarterly revenue—meaningful for $20.7M market cap company). Q2 conversion risk remains. Gross margin expansion and cash generation are positive, but Reviv3 dilution modest. Business inflection pending.
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.